DSE : LIBRAINFU
Libra Infusions Limited — Key statistics
Pharmaceutical Preparations · Bangladesh
Last price 555.9 BDT (At close: Nov 1, 2026) · Market cap 1.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Technical report: trend, RSI, support and resistance, charts
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.25B |
| Enterprise Value | n/a |
Dates
| Measure | Value |
|---|
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.25M |
| Shares Outstanding | 2.25M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Ratios
| Measure | Value |
|---|
| PE Ratio | 790.57 |
| Forward PE | n/a |
| PS Ratio | 6.36 |
| PB Ratio | 0.66 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 85.38 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.65 |
| Quick Ratio | 0.22 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | 31.80 |
| Debt / FCF | n/a |
| Interest Coverage | 0.97 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 0.08% |
| Return on Assets (ROA) | 0.36% |
| Return on Invested Capital (ROIC) | 0.56% |
| Return on Capital Employed (ROCE) | 0.81% |
| Weighted Average Cost of Capital (WACC) | 2.51% |
| Revenue Per Employee | 281,876 |
| Profits Per Employee | 2,266 |
| Employee Count | 699 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 1.59 |
Taxes
| Measure | Value |
|---|
| Income Tax | 674,316 |
| Effective Tax Rate | 29.86% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.22 |
| 52-Week Price Change | -20.73% |
| 50-Day Moving Average | 572.96 |
| 200-Day Moving Average | 621.78 |
| Relative Strength Index (RSI) | 48.28 |
| Average Volume (20 Days) | 5,924 |
Shortselling
| Measure | Value |
|---|
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 197.03M |
| Gross Profit | 77.89M |
| Operating Income | 22.22M |
| Pretax Income | 2.26M |
| Net Income | 1.58M |
| EBITDA | 28.79M |
| EBIT | 22.22M |
| Earnings Per Share (EPS) | 0.70 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 14.39M |
| Total Debt | 915.38M |
| Net Cash | -901.00M |
| Net Cash Per Share | -399.93 |
| Equity (Book Value) | 1.91B |
| Book Value Per Share | 845.97 |
| Working Capital | -104.18M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 14.67M |
| Capital Expenditures | -19.91M |
| Depreciation & Amortization | 6.57M |
| Net Borrowing | 10.62M |
| Free Cash Flow | -5.24M |
| FCF Per Share | -2.33 |
Margins
| Measure | Value |
|---|
| Gross Margin | 39.53% |
| Operating Margin | 11.28% |
| Pretax Margin | 1.15% |
| Profit Margin | 0.80% |
| EBITDA Margin | 14.61% |
| EBIT Margin | 11.28% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | 1.00 |
| Dividend Yield | 0.18% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 0.18% |
| Earnings Yield | 0.13% |
| FCF Yield | -0.42% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.79 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |